No Benefit Seen From Adjuvant Celecoxib in ERBB2 - Negative Breast Cancer

Disease - free survival did not improve with two years of celecoxib versus placebo in ERBB2 - negative breast cancer
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news